Fibroblast growth factor receptors - Revision history

Michael at 16:23, 8 March 2024

2024-03-08T16:23:36Z

← Older revision		Revision as of 16:23, 8 March 2024
Line 1:		Line 1:
	'''Fibroblast growth factor receptor''', abbreviated '''FGFR''', a molecule that transmit growth signals for fibroblasts.		'''Fibroblast growth factor receptor''', abbreviated '''FGFR''', a molecule that transmit growth signals for fibroblasts.
	:''FGFR2'' and ''FGFR3'' redirect here.		''FGFR2'' and ''FGFR3'' redirect here.

	An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal \|vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A \|title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review \|journal=J Cancer Res Clin Oncol \|volume=149 \|issue=8 \|pages=4915–4923 \|date=July 2023 \|pmid=36307559 \|doi=10.1007/s00432-022-04428-w \|url=}}</ref><ref name=pmid33731335>{{cite journal \|vauthors=Al-Obaidy KI, Cheng L \|title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder \|journal=J Clin Pathol \|volume=74 \|issue=8 \|pages=491–495 \|date=August 2021 \|pmid=33731335 \|doi=10.1136/jclinpath-2020-207115 \|url=}}</ref>		An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal \|vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A \|title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review \|journal=J Cancer Res Clin Oncol \|volume=149 \|issue=8 \|pages=4915–4923 \|date=July 2023 \|pmid=36307559 \|doi=10.1007/s00432-022-04428-w \|url=}}</ref><ref name=pmid33731335>{{cite journal \|vauthors=Al-Obaidy KI, Cheng L \|title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder \|journal=J Clin Pathol \|volume=74 \|issue=8 \|pages=491–495 \|date=August 2021 \|pmid=33731335 \|doi=10.1136/jclinpath-2020-207115 \|url=}}</ref>

Michael at 16:23, 8 March 2024

2024-03-08T16:23:27Z

← Older revision		Revision as of 16:23, 8 March 2024
Line 1:		Line 1:
	'''Fibroblast growth factor receptor''', abbreviated '''FGFR''', a molecule that transmit growth signals for fibroblasts.		'''Fibroblast growth factor receptor''', abbreviated '''FGFR''', a molecule that transmit growth signals for fibroblasts.
			:''FGFR2'' and ''FGFR3'' redirect here.

	An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal \|vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A \|title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review \|journal=J Cancer Res Clin Oncol \|volume=149 \|issue=8 \|pages=4915–4923 \|date=July 2023 \|pmid=36307559 \|doi=10.1007/s00432-022-04428-w \|url=}}</ref><ref name=pmid33731335>{{cite journal \|vauthors=Al-Obaidy KI, Cheng L \|title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder \|journal=J Clin Pathol \|volume=74 \|issue=8 \|pages=491–495 \|date=August 2021 \|pmid=33731335 \|doi=10.1136/jclinpath-2020-207115 \|url=}}</ref>		An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal \|vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A \|title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review \|journal=J Cancer Res Clin Oncol \|volume=149 \|issue=8 \|pages=4915–4923 \|date=July 2023 \|pmid=36307559 \|doi=10.1007/s00432-022-04428-w \|url=}}</ref><ref name=pmid33731335>{{cite journal \|vauthors=Al-Obaidy KI, Cheng L \|title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder \|journal=J Clin Pathol \|volume=74 \|issue=8 \|pages=491–495 \|date=August 2021 \|pmid=33731335 \|doi=10.1136/jclinpath-2020-207115 \|url=}}</ref>

Michael at 16:22, 8 March 2024

2024-03-08T16:22:57Z

← Older revision		Revision as of 16:22, 8 March 2024
Line 3:		Line 3:
	An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal \|vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A \|title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review \|journal=J Cancer Res Clin Oncol \|volume=149 \|issue=8 \|pages=4915–4923 \|date=July 2023 \|pmid=36307559 \|doi=10.1007/s00432-022-04428-w \|url=}}</ref><ref name=pmid33731335>{{cite journal \|vauthors=Al-Obaidy KI, Cheng L \|title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder \|journal=J Clin Pathol \|volume=74 \|issue=8 \|pages=491–495 \|date=August 2021 \|pmid=33731335 \|doi=10.1136/jclinpath-2020-207115 \|url=}}</ref>		An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal \|vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A \|title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review \|journal=J Cancer Res Clin Oncol \|volume=149 \|issue=8 \|pages=4915–4923 \|date=July 2023 \|pmid=36307559 \|doi=10.1007/s00432-022-04428-w \|url=}}</ref><ref name=pmid33731335>{{cite journal \|vauthors=Al-Obaidy KI, Cheng L \|title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder \|journal=J Clin Pathol \|volume=74 \|issue=8 \|pages=491–495 \|date=August 2021 \|pmid=33731335 \|doi=10.1136/jclinpath-2020-207115 \|url=}}</ref>

	Anti-FGFR therapy is used in:		==Anti-FGFR therapy==
			It is used in:
	*[[Urothelial carcinoma]].<ref name=pmid33731335/>		*[[Urothelial carcinoma]].<ref name=pmid33731335/>
	*Hepatobiliary cancers.{{fact}}		*Hepatobiliary cancers.{{fact}}

Michael at 16:22, 8 March 2024

2024-03-08T16:22:28Z

← Older revision		Revision as of 16:22, 8 March 2024
Line 1:		Line 1:
	'''Fibroblast growth factor receptor''', abbreviated '''FGFR''', a molecule that transmit growth signals for fibroblasts.		'''Fibroblast growth factor receptor''', abbreviated '''FGFR''', a molecule that transmit growth signals for fibroblasts.

	An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal \|vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A \|title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review \|journal=J Cancer Res Clin Oncol \|volume=149 \|issue=8 \|pages=4915–4923 \|date=July 2023 \|pmid=36307559 \|doi=10.1007/s00432-022-04428-w \|url=}}</ref><ref>{{cite journal \|vauthors=Al-Obaidy KI, Cheng L \|title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder \|journal=J Clin Pathol \|volume=74 \|issue=8 \|pages=491–495 \|date=August 2021 \|pmid=33731335 \|doi=10.1136/jclinpath-2020-207115 \|url=}}</ref>		An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal \|vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A \|title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review \|journal=J Cancer Res Clin Oncol \|volume=149 \|issue=8 \|pages=4915–4923 \|date=July 2023 \|pmid=36307559 \|doi=10.1007/s00432-022-04428-w \|url=}}</ref><ref name=pmid33731335>{{cite journal \|vauthors=Al-Obaidy KI, Cheng L \|title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder \|journal=J Clin Pathol \|volume=74 \|issue=8 \|pages=491–495 \|date=August 2021 \|pmid=33731335 \|doi=10.1136/jclinpath-2020-207115 \|url=}}</ref>

			Anti-FGFR therapy is used in:
			*[[Urothelial carcinoma]].<ref name=pmid33731335/>
			*Hepatobiliary cancers.{{fact}}

	==See also==		==See also==

Michael at 16:19, 8 March 2024

2024-03-08T16:19:23Z

← Older revision		Revision as of 16:19, 8 March 2024
Line 2:		Line 2:

	An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal \|vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A \|title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review \|journal=J Cancer Res Clin Oncol \|volume=149 \|issue=8 \|pages=4915–4923 \|date=July 2023 \|pmid=36307559 \|doi=10.1007/s00432-022-04428-w \|url=}}</ref><ref>{{cite journal \|vauthors=Al-Obaidy KI, Cheng L \|title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder \|journal=J Clin Pathol \|volume=74 \|issue=8 \|pages=491–495 \|date=August 2021 \|pmid=33731335 \|doi=10.1136/jclinpath-2020-207115 \|url=}}</ref>		An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal \|vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A \|title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review \|journal=J Cancer Res Clin Oncol \|volume=149 \|issue=8 \|pages=4915–4923 \|date=July 2023 \|pmid=36307559 \|doi=10.1007/s00432-022-04428-w \|url=}}</ref><ref>{{cite journal \|vauthors=Al-Obaidy KI, Cheng L \|title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder \|journal=J Clin Pathol \|volume=74 \|issue=8 \|pages=491–495 \|date=August 2021 \|pmid=33731335 \|doi=10.1136/jclinpath-2020-207115 \|url=}}</ref>

			==See also==
			*[[Classification of urothelial carcinoma by immunohistochemistry]].

	==References==		==References==

Michael at 16:18, 8 March 2024

2024-03-08T16:18:10Z

← Older revision		Revision as of 16:18, 8 March 2024
Line 6:		Line 6:
	{{Reflist\|1}}		{{Reflist\|1}}

	[[Category:Molecular ~~Pathology~~]]		[[Category:Molecular pathology]]

Michael: create

2024-03-08T16:17:42Z

create

New page

'''Fibroblast growth factor receptor''', abbreviated '''FGFR''', a molecule that transmit growth signals for fibroblasts.

An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal |vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A |title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review |journal=J Cancer Res Clin Oncol |volume=149 |issue=8 |pages=4915–4923 |date=July 2023 |pmid=36307559 |doi=10.1007/s00432-022-04428-w |url=}}</ref><ref>{{cite journal |vauthors=Al-Obaidy KI, Cheng L |title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder |journal=J Clin Pathol |volume=74 |issue=8 |pages=491–495 |date=August 2021 |pmid=33731335 |doi=10.1136/jclinpath-2020-207115 |url=}}</ref>

==References==
{{Reflist|1}}

[[Category:Molecular Pathology]]